Clinical studies have demonstrated an average waist circumference reduction of approximately 2.6 cm (1 inch) after a single Liposonix treatment.
The company also announced that more than two million procedures have been completed around the world using its portfolio of aesthetic energy device (AED) products. This industry milestone reflects significant advances made over the past decade, starting with the introduction of Thermage's radiofrequency skin tightening technology system in 2002 and its most recent evolution incorporates proprietary Comfort Pulse Technology that delivers more therapeutic heat across the treatment area, allowing for a more efficient skin tightening treatment.
Thermage was followed in 2004 by Fraxel, a revolutionary fractional laser treatment to resurface the skin and address sun damage and unwanted pigmentation. In 2007, the Isolaz acne fighting system using a gentle vacuum to purify pores and intense pulsed light to kill bacteria was launched. An at-home companion device to Isolaz, CLARO began selling at retail outlets in 2010. More recently, Clear + Brilliant a new, less-invasive approach to laser skin enhancement to prevent the unwanted signs of aging was developed utilising Fraxel technology, and finally, this year Liposonix.
"Over the years, Solta has helped transform aesthetic medicine - with its deep roots in rigorous science by providing gold-standard energy technologies used to treat patients who sought effective and safe skin treatments," said Roy G. Geronemus, MD, clinical professor of dermatology at New York University Medical Centre and director of the Laser & Skin Surgery Centre of New York.
"Solta products have been go-to treatment solutions for my patients looking for non-invasive options for everything from skin resurfacing and tightening to preventative and maintenance care to slow down the aging process to clearing acne and now fat reduction. I have been using Solta's entire line of aesthetic energy devices not only because patients ask for them by name but also because the products deliver their promised results time after time."
"More than two million treatments worldwide is an important milestone for Solta Medical. With this achievement, we continue to demonstrate our leadership position in the market through the growing acceptance of our brand portfolio around the globe," said Stephen J. Fanning, chairman of the board, president and CEO of Solta Medical.
"We are continually investing in R&D and looking to introduce new, safe, innovative devices that deliver the best possible results for physicians and their patients in more than 100 markets around the world."
For more information on Solta Medical, go to www.Solta.com.
